Navigation Links
Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Date:2/2/2011

f the Amarin's management team to successfully launch and commercialize products or enter into a strategic partnership for such launch. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: anticipated operating losses and the likely need for additional capital to fund future operations; uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that historical clinical trial results, including the results of the MARINE trial and historical enrolment and randomization rates, may not be predictive of future results; uncertainties relating to the timing of data collection and analysis for the ANCHOR and MARINE trials; dependence on third-party manufacturers, suppliers and collaborators; significant competition; loss of key personnel; and uncertainties associated with market acceptance and adequacy of reimbursement, technological change and government regulation. A further list and description of these risks, uncertainties and other matters can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Proposed Public Offering of American Depositary Shares
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices ... has big ideas for 2014 in production and sales ... to produce high-quality, low-cost, DRM-free ebooks and to use ... , The first major development will be bookstore sales ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Robert G. Johnson, Jr. Resigns as President and ... Near-Term Commercial Opportunities, HAYWARD, Calif., Feb. 28 ... announced that Robert G. Johnson, Jr.,M.D., Ph.D., has ... a,member of Kosan,s Board of Directors. Helen S. ...
... payment, WILMINGTON, N.C., Feb. 28 PPD, ... Limited,s new drug,application (NDA) for alogliptin, a highly ... diabetes, has been accepted for filing by the ... to develop the,compound., Under PPD,s agreement with ...
... Feb. 28 The Center for Molecular,Medicine (CMM) today ... the,nation to offer a new, FDA-approved test that will ... CMM (http://www.cmmdx.org ) is offering the CellSearch(TM) System ... new tool in managing,patients with metastatic prostate cancer (MPC). ...
Cached Biology Technology:Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and Drug Administration 2Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer 2
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... serious conditions such as heart disease, epilepsy and pain, ... Unfortunately, there is still much scientists do not know ... unexpected insight into the structure of sodium channels and, ... which are responsible for ,fine-tuning, the activity of the ... edition of the Journal of Biological Chemistry . ...
(Date:4/17/2014)... BLOOMINGTON, Ind. -- Indiana University researchers have detected new ... with diabetes. This discovery could have far-reaching implications for ... the care of over 25 million Americans. , "We ... the retinas at such early stages," said Ann Elsner, ... Optometry and lead author of the study. "We set ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... nature,s repository of chemicals in plants, microbes, and marine ... be a major theme of a five-day scientific conference ... 1,200 natural products researchers from around the world. ... the City University of New York, and other New ...
... Imagine millions of cancer cells organized in thousands of small ... die, you have a candidate for a cancer drug. But ... Opinion on Drug Discovery argues that these 2D models ... effects in the body and may often give researchers misleading ...
... Fla. (July 19, 2012) A study comparing whether endothelial ... from human umbilical cord blood are more proliferative and better ... from human placenta are more vasculogenic., The study, carried out ... in a recent issue of Cell Medicine [2(3)] ...
Cached Biology News:Nature as a source of new medicines subject of ICNPR in NYC 2Nature as a source of new medicines subject of ICNPR in NYC 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Blood vessel forming potential of stem cells from human placenta and umbilical cord blood 2
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... is a 2-color staining method for labeling ... detect apoptotic cells by flow cytometry. The ... for measuring apoptosis in cells, including positive ... performance; washing, reaction and rinsing buffers for ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: